MedTrace Logo

Stroke Prevention in Sickle Cell Anemia (STOP 2)

NCT00006182 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-02-18

No results posted yet for this study

Summary

To determine how long blood transfusions are needed for primary stroke prevention. Also, to determine the duration of risk associated with abnormal transcranial Doppler ultrasound (TCD) and to determine the specificity of the stroke risk model developed in STOP 1 in patients with abnormal TCD measurements.

Conditions

  • Blood Disease
  • Cerebrovascular Accident
  • Anemia, Sickle Cell

Interventions

PROCEDURE

Blood Transfusion

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Robert Adams · Augusta University

  • Donald Brambilla · New England Research Institutes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
2 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Completion
2006-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006182 on ClinicalTrials.gov